AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AnaptysBio 2025 Q3 Earnings Record Revenue and 146% Net Income Surge
Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Wednesday, Nov 5, 2025 5:14 am ET1min read
Aime SummaryAnaptysBio (ANAB) delivered a dramatic turnaround in its fiscal 2025 Q3 earnings, reporting $76.32 million in revenue and $15.11 million in net income. The results far exceeded expectations, . CEO Daniel Faga outlined plans to separate biopharma and royalty assets by 2026 while highlighting Jemperli’s $785 million YTD sales and rosnilimab’s promising Phase 2b data.
<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762337621623.jpg.png" style="max-width:100%;">
Revenue
AnaptysBio’s total revenue soared to $76.32 million in Q3 2025, . This growth was driven entirely by collaboration revenue, . The year-over-year leap underscores the company’s ability to capitalize on milestone and royalty payments from partnerships, particularly with GSK’s Jemperli.
Earnings/Net Income
The company achieved a historic turnaround, , . Earnings per share (EPS) turned positive at $0.54, . This marks a significant milestone after 12 consecutive years of quarterly losses.
Price Action
AnaptysBio’s stock price experienced mixed post-earnings movement. , but gained 12.28% month-to-date. The volatility reflects investor skepticism amid a broader market rally, though the stock has surged 172.2% year-to-date, .
Post-Earnings Price Action Review
The stock’s immediate post-earnings reaction was tempered by short-term selling pressure, . However, the 12.28% monthly gain suggests underlying optimism about the company’s strategic shift and Jemperli’s commercial potential. Analysts remain cautious, , .
CEO Commentary
. , . , , were cited as key growth drivers.
Guidance
. . , .
Additional News
AnaptysBio announced plans to spin off its biopharma and royalty operations by 2026, aiming to streamline growth and enhance shareholder value. , . Additionally, , . .
<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762337621623.jpg.png" style="max-width:100%;">
Daily Earnings
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Brown-Forman A 2026 Q2 Earnings Revenue Falls 5.4%, Net Income Drops 13.2%
Dec.05 2025
Argan 2026 Q3 Earnings Record Net Income and $3B Backlog Despite Revenue Dip
Dec.05 2025
John Wiley Sons B 2026 Q2 Earnings EPS Rises 13.3% Despite Revenue Decline
Dec.04 2025
John Wiley Sons A 2026 Q2 Earnings Strong EPS Growth Amid Revenue Decline
Dec.04 2025
Titan Machinery 2026 Q3 Earnings Net Income Drops 30.1% Amid Revenue Decline
Dec.04 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet